Relapsed or refractory diffuse large B-cell Lymphoma CAR-T Cell Therapy is superior to Standard Second-line Therapy

被引：0
|
作者：
Ruedesheim, Sabine M.
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：231 / 231
页数：1
相关论文
共 50 条
  • [1] Second-Line Chimeric Antigen Receptor T Cell Therapy (CAR-T) As Standard of Care for Relapsed-Refractory Large B-Cell Lymphoma (LBCL)
    Dahiya, Saurabh
    Spiegel, Jay Y.
    Lee, Dasom
    Mohammed, Turab
    Lutfi, Forat
    Goyal, Anmol
    Hana, Caroline
    Chavez, Julio C.
    Ionescu, Filip
    Frank, Matthew J.
    Bharadwaj, Sushma
    Sandoval-Sus, Jose
    Beitinjaneh, Amer M.
    Lekakis, Lazaros J.
    McGuirk, Joseph P.
    Locke, Frederick L.
    Miklos, David B.
    Jain, Michael D.
    BLOOD, 2023, 142
  • [2] The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma
    Albanyan, Omar
    Chavez, Julio
    Munoz, Javier
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [3] The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma
    Albanyan, Omar
    Chavez, Julio
    Munoz, Javier
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [4] CAR-T cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis
    Shargian, Liat
    Raanani, Pia
    Yeshurun, Moshe
    Gafter-Gvili, Anat
    Gurion, Ronit
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 200 (01) : E4 - E5
  • [5] Management of relapsed or refractory large B-cell lymphoma in patients ineligible for CAR-T cell therapy
    Perrone, Salvatore
    Lopedote, Paolo
    Levis, Mario
    Di Rocco, Alice
    Smith, Stephen Douglas
    EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (03) : 215 - 232
  • [6] Second-line Treatment With CAR T-Cell Therapy for Large B-Cell Lymphoma
    Lutfi, Forat
    Patel, Ameet
    Mehta, Jasmine
    Goyal, Anmol
    Dahiya, Saurabh
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (04) : 170 - 178
  • [7] Role of bridging RT in relapsed/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: a multicenter study
    Stefania Bramanti
    Daniele Mannina
    Annalisa Chiappella
    Beatrice Casadei
    Chiara De Philippis
    Laura Giordano
    Pierina Navarria
    Pietro Mancosu
    Daniela Taurino
    Marta Scorsetti
    Carmelo Carlo-Stella
    Pierluigi Zinzani
    Armando Santoro
    Paolo Corradini
    Bone Marrow Transplantation, 2025, 60 (1) : 32 - 38
  • [8] Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma: Is It Time to Consider CAR-T for All
    Zelenetz, Andrew D.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (12): : 1764 - 1766
  • [9] CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?
    Westin, Jason
    Sehn, Laurie H.
    BLOOD, 2022, 139 (18) : 2737 - 2746
  • [10] Is chimaeric antigen receptor T-cell therapy really superior to standard of care as second-line therapy for large B-cell lymphoma?
    Saiz, Luis Carlos
    Leache, Leire
    Gutierrez-Valencia, Marta
    Erviti, Juan
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 200 (01) : E6 - E7
12345